A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

被引：0
|
作者：
Nikol Snoeren
Emile E Voest
Andre M Bergman
Otilia Dalesio
Henk M Verheul
Rob AEM Tollenaar
Joost RM van der Sijp
Sander B Schouten
Inne HM Borel Rinkes
R van Hillegersberg
机构：
[1] University Medical Center Utrecht,Department of Surgical Oncology
[2] University Medical Center Utrecht,Department of Medical Oncology
[3] Antonie van Leeuwenhoek Hospital,Department of Medical Oncology
[4] Antonie van Leeuwenhoek Hospital,Department of Biometrics
[5] VU Medical Center De Boelelaan 1117,Department of Medical Oncology
[6] Department of Surgery,undefined
[7] Leiden,undefined
[8] Department of Surgery,undefined
来源：
BMC Cancer | / 10卷
关键词：
Vascular Endothelial Growth Factor; Bevacizumab; Liver Metastasis; Disease Free Survival; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY
    Leone, F.
    Marino, D.
    Artale, S.
    Cagnazzo, C.
    Cascinu, S.
    Martoni, A. A.
    Sobrero, A.
    Tampellini, M.
    Siena, S.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 205 - 206
  • [32] SHORT-COURSE RADIATION THERAPY, NEOADJUVANT BEVACIZUMAB, CAPECITABINE AND OXALIPLATIN, AND RADICAL RESECTION OF PRIMARY TUMOUR AND METASTASES IN PRIMARY STAGE IV RECTAL CANCER: A PHASE II MULTICENTER STUDY OF THE DUTCH COLORECTAL CANCER GROUP
    Van Dijk, T. H.
    Hospers, G. A. P.
    Beukema, J. C.
    Beets, G. L.
    Gelderblom, A. J.
    De Jong, K. P.
    Rutten, H. J.
    Van de Velde, C. J. H.
    Wiggers, T.
    Havenga, K.
    ANNALS OF ONCOLOGY, 2010, 21 : I51 - I51
  • [33] FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
    Iwamoto, S.
    Takahashi, T.
    Tamagawa, H.
    Nakamura, M.
    Munemoto, Y.
    Kato, T.
    Hata, T.
    Denda, T.
    Morita, Y.
    Inukai, M.
    Kunieda, K.
    Nagata, N.
    Kurachi, K.
    Ina, K.
    Ooshiro, M.
    Shimoyama, T.
    Baba, H.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1427 - 1433
  • [34] Phase III trial of capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV plus oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer(MCRC)
    Rothenberg, M.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J.
    Goel, R.
    Gollins, S.
    Siu, L.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2007, 18 : VII17 - VII18
  • [35] Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX plus FP plus BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
    Nagasaka, T.
    Inada, R.
    Ojima, H.
    Noura, S.
    Tanioka, H.
    Munemoto, Y.
    Shimada, Y.
    Ishibashi, K.
    Shindo, Y.
    Kagawa, Y.
    Tomibayashi, A.
    Okamoto, K.
    Tsuji, A.
    Tsuji, Y.
    Yamaguchi, S.
    Sawaki, A.
    Mishima, H.
    Shimokawa, M.
    Okajima, M.
    Yamaguchi, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
    Scheithauer, W.
    Prager, G.
    Greil, R.
    Mlineritsch, B.
    Schaberl-Moser, R.
    Gerger, A.
    Laengle, F.
    Viragos-Toth, I.
    Andel, J.
    Pichler, A.
    Pecherstorfer, M.
    Kretschmer, A.
    Seebacher, A.
    Jagdt, B.
    Eisterer, W.
    Krippl, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] 'LIMITED TREATMENT DURATION AND RE-INDUCTION WITH THE SAME REGIMEN ON PROGRESSION' VS 'TREATMENT UNTIL PROGRESSION' WITH BIWEEKLY CAPECITABINE plus OXALIPLATIN ± BEVACIZUMAB IN PATIENTS (PTS) WITH ADVANCED COLORECTAL CANCER (CRC): A RANDOMISED PHASE II STUDY
    Scheithauer, W.
    Kornek, G.
    Aigner, K.
    Schaberl-Moser, R.
    Keil, F.
    Andel, J.
    Renner, F.
    Eisterer, W.
    Balcke, P.
    Schueller, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 169 - 169
  • [38] Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
    Bianconi, Daniela
    Herac, Merima
    Posch, Florian
    Schmeidl, Margit
    Unseld, Matthias
    Kieler, Markus
    Brettner, Robert
    Muellauer, Leonhard
    Riedl, Jakob
    Gerger, Armin
    Scheithauer, Werner
    Prager, Gerald
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [39] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [40] Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal Cancer Group.
    van Dijk, T. H.
    Havenga, K.
    Beukema, J.
    Beets, G. L.
    Gelderblom, H.
    de Jong, K. P.
    Rutten, H. J.
    Van de Velde, C. J.
    Wiggers, T.
    Hospers, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345